#T-DXd
LightNews LightNews
cannonfodderclub.bsky.social
This is a Mobei-jun statue I sculpted for the wonderful
@alikamorein.bsky.social's "wet t-shirt" prompt - part of the super fun @moshangevents.bsky.social DxD Summer Edition event!!!

#moshang #mobeijun #shangqinghu #svsss
May 5, 2026 at 8:41 PM
oncodaily.bsky.social
FDA Approves T-DXd for HR+, HER2-Low/Ultralow Breast Cancer Treatment

oncodaily.com/insight/234405

#BreastCancer #Cancer #FDA #CancerCare #OncoDaily #Oncology #TheDESTINY-04Trial #TrastuzumabDeruxtecan #Medicine #Health
FDA Approves T-DXd for HR+, HER2-Low/Ultralow Breast Cancer Treatment - OncoDaily
FDA Approves T-DXd for HR+, HER2-Low/Ultralow Breast Cancer Treatment / Aditya Bardia, Breast Cancer, cancer, Carlos H. Barrios, FDA, Gargi Patel, Giuseppe
oncodaily.com
January 29, 2025 at 10:42 PM
tmprowell.bsky.social
NEW #Oncology:
EGFR expression mediates resistance to T-DXd (EGFR overexpression ⬇️ HER2 homodimerization & HER2/ADC internalization)

Combining with EGFR mAbs restored HER2/ADC trafficking & ⬆️ activity in nonclinical models

#DrugDevelopment #OncoSky

www.cell.com/cell-reports...
EGFR-directed antibodies promote HER2 ADC internalization and efficacy
Gupta et al. demonstrate that high EGFR expression mediates resistance to HER2 antibody drug conjugates (ADCs) including trastuzumab deruxtecan (T-DXd) by limiting HER2/ADC internalization. The additi...
www.cell.com
November 12, 2024 at 12:33 PM
elisaagostinetto.bsky.social
At #SABCS24 LBA session - @dradityabardia on Efficacy and Safety of T-DXd by Pace of Disease Progression on Prior Endocrine-Based Therapy in DESTINY-Breast06

T-DXd ⬆️PFS regardless of time to progression on 1st line CDK4/6i+ET or type of endocrine resistance

@oncoalert.bsky.social
December 11, 2024 at 12:38 AM
jlist.com
How many times have you seen Rias' boobs? Sauce is High School DxD.

J-List has added lots of new ero toys to the site this week! Find them all here: jlist.com/shop/adult-t...
September 24, 2026 at 2:10 AM
oncodaily.bsky.social
FDA Approves T-DXd for HR+, HER2-Low/Ultralow Breast Cancer Treatment
@fda.gov

oncodaily.com/insight/234405

#BreastCancer #Cancer #FDA #OncoDaily #Oncology #Medicine #DESTINY-Breast04Trial #Trastuzumab #Deruxtecan #Health
FDA Approves T-DXd for HR+, HER2-Low/Ultralow Breast Cancer Treatment - OncoDaily
FDA Approves T-DXd for HR+, HER2-Low/Ultralow Breast Cancer Treatment / Aditya Bardia, Breast Cancer, cancer, Carlos H. Barrios, FDA, Gargi Patel, Giuseppe
oncodaily.com
February 5, 2025 at 6:07 PM
oncodaily.bsky.social
How to Treat Patients with Metastatic Breast Cancer After Prior Exposure to T-DXd? - Paolo Tarantino

@ptarantinomd.bsky.social

oncodaily.com/insight/paol...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #BreastCancer #T-DXd
Paolo Tarantino: How to Treat Patients with Metastatic Breast Cancer After Prior Exposure to T-DXd? - OncoDaily
Paolo Tarantino: How to Treat Patients with Metastatic Breast Cancer After Prior Exposure to T-DXd? / Adrienne G. Waks, cancer, Cary P. Gross, Do Lee, Eric P.
oncodaily.com
August 16, 2025 at 8:11 PM
jlist.com
It's important for a young man to focus. Sauce is High School DxD.

J-Lsit has lots of amazing stress-relief products for you to "focus" on. Browse here! jlist.com/shop/adult-t...
November 19, 2025 at 3:10 AM
oncodaily.bsky.social
DESTINY-Breast06 Trial Updates at ESMO Breast 2025 Confirms T-DXd Efficacy in HER2-Low and Ultralow mBC
@myesmo.bsky.social @eliasegui.bsky.social

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #DESTINY-Breast06 #ESMOBreast25 #BreastCancer
DESTINY-Breast06 Trial Updates at ESMO Breast 2025 Confirms T-DXd Efficacy in HER2-Low and Ultralow Metastatic Breast Cancer - OncoDaily
DESTINY-Breast06 trial shows T-DXd improves PFS over chemo in HR+/HER2-low mBC after endocrine therapy. Latest results from ESMO Breast 2025.
oncodaily.com
May 18, 2025 at 5:48 PM
oncodaily.bsky.social
Discussing T-DXd toxicities in breast cancer at a thought-provoking meeting in Lisbon - Olubukola Ayodele
@bookiephronesis.bsky.social

oncodaily.com/blog/olubuko...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Lisbon #BreastCancer #TDXd
Olubukola Ayodele: Discussing T-DXd toxicities in breast cancer at a thought-provoking meeting in Lisbon - OncoDaily
Olubukola Ayodele shares insights from a Lisbon meeting on managing T-DXd toxicities in metastatic HER2-positive breast cancer.
oncodaily.com
April 30, 2025 at 2:35 PM
drsarahsammons.bsky.social
Dato-Dxd approved in Metastatic HR+, HER-neg Breast Cancer.

Same payload as T-Dxd and bit less potent.

Unknown activity after T-Dxd or saci. Could consider for true HER2- zero as first line chemo or in subsequent lines. #bcsm

www.targetedonc.com/view/fda-app...
FDA Approves Dato-DXd in HR+/HER2– Breast Cancer
As supported by data from the phase 3 TROPION-Breast01 trial, datopotamab deruxtecan is now an FDA-approved treatment for patients with HR-positive, HER2-negative breast cancer.
www.targetedonc.com
January 17, 2025 at 7:21 PM
itsnotpink.bsky.social
Looking forward to seeing the many #SABCS24 posters related to dosing changes, especially CDK4/6s.

But I wish there was more info on T-DXd dose reductions!
November 13, 2024 at 3:56 PM
ncasasanta.bsky.social
Looking forward to seeing the data for neoadjuvant T-DXd ➡️ THP in patients with high risk, locally advanced HER2+ breast cancer! 💉
Rates of ILD similar among T-DXd/THP vs ddAC-THP arms🫁
oncoalert.bsky.social The OncoAlert Network 🚨 @oncoalert.bsky.social · May 7
NEWS FROM INDUSTRY🚨 Source AstraZeneca
DESTINY-Breast11 Update

DESTINY-Breast11 sees trastuzumab deruxtecan followed by paclitaxel, trastuzumab, and pertuzumab improved pathologic complete response rates compared to the standard neoadjuvant regimen

www.astrazeneca.com/media-centre...
May 8, 2025 at 12:55 AM
jlist.com
It can be so hard to concentrate on magic, can't it? Sauce is High School DxD.

J-List has awesome new onaholes from Japan's best makers for you. See jlist.com/shop/adult-t...
September 8, 2026 at 11:57 AM
oncodaily.bsky.social
DESTINY-Breast06 Trial Updates at ESMO Breast 2025 Confirms T-DXd Efficacy in HER2-Low and Ultralow Metastatic Breast Cancer
@myesmo.bsky.social

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #DESTINY-Breast06 #ESMOBreast25 #BreastCancer #MBC
DESTINY-Breast06 Trial Updates at ESMO Breast 2025 Confirms T-DXd Efficacy in HER2-Low and Ultralow Metastatic Breast Cancer - OncoDaily
DESTINY-Breast06 trial shows T-DXd improves PFS over chemo in HR+/HER2-low mBC after endocrine therapy. Latest results from ESMO Breast 2025.
oncodaily.com
May 16, 2025 at 10:30 PM
onclive.bsky.social
First-Line T-DXd ± Pertuzumab Yields Durable Responses in HER2+ Metastatic Breast Cancer #BCSM

www.onclive.com/view/first-l...
First-Line T-DXd ± Pertuzumab Yields Durable Responses in HER2+ Metastatic Breast Cancer
T-DXd with or without pertuzumab produced responses in first-line, HER2-positive metastatic breast cancer.
www.onclive.com
March 10, 2025 at 8:03 PM
rsm2800.bsky.social
DESTINY-Breast06 trial results presented at #SABCS24. Enhertu seems to be more efficacious than chemo (Xeloda, Abraxane, or paclitaxel) for pts w/ ER+ MBC with and without primary endocrine resistance and for those with/without liver mets www.onclive.com/view/t-dxd-i...
T-DXd Improves PFS Irrespective of Time to Progression, Type of Endocrine Resistance in HER2-Low/-Ultralow Metastatic Breast Cancer
T-DXd improved PFS vs treatment of physician’s choice in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer.
www.onclive.com
December 12, 2024 at 3:16 PM
morningflamesword.bsky.social
#TeamMBJ | #DxD | #MoShang

Thank you @alikamorein.bsky.social for the @moshangevents.bsky.social DxD prompt!
Prompt # 69: Wet T-shirt Contest MBJ nods, standing in a drenched transparent tee and 1st place ribbon as SQH (XF) touches his arm and says "You, uh, heh- Mentioned needing a RIDE out of here, Gorgeous?" with hearts in the bubble. SQH has a small blush. It's unclear whether MBJ is blushing or sunburnt. SY is ranting off screen over LBH's unfair loss since MBJ was just some guy who wandered in from the water park.
April 27, 2026 at 12:44 AM
biologist077.bsky.social
Woah, new FDA approval means some folks with early HER2+ breast cancer might have a better shot at remission. In a trial, a drug combo (T-DXd) given *before* surgery led to 67% of patients showing no signs of cancer after treatment. 🤯 That's a pathologic complete response!
FDA Expands T-DXd With 2 New Indications in HER2-Positive Early Breast Cancer
The FDA has expanded the use of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu), an antibody-drug conjugate, for two new indications in adults with HER2-positive early-stage breast cancer. This appro
www.pharmacytimes.com
May 20, 2026 at 2:03 PM
joshdragomd.bsky.social
In this manuscript, online today in Cancer Discovery, we investigate target-mediated resistance to ADCs, and propose ways to overcome it.

aacrjournals.org/cancerdiscov...
Trastuzumab Deruxtecan (T-DXd) Resistance via Loss of HER2 Expression and Binding
Abstract. T-DXd is clinically beneficial in HER2 positive and HER2 low metastatic breast cancer. However, therapeutic resistance emerges over time in most patients, with poorly defined resistance mech...
aacrjournals.org
November 10, 2025 at 4:55 PM
biologist077.bsky.social
Good news: A drug called T-DXd significantly reduced the risk of cancer returning in HER2+ early breast cancer patients after initial treatment. After 3 years, 92% of patients on T-DXd were cancer-free, compared to 84% on the standard treatment.
FDA Grants Priority Review to T-DXd in HER2+ Early Breast Cancer
The FDA has accepted a supplemental biologics license application and granted priority review for fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) as a treatment for adult patients with HER2-positive
www.cancernetwork.com
March 10, 2026 at 2:02 PM
jlist.com
I love Akeno so much. Sauce is High School DxD.

What amazing new ero toys did J-List post for you this week, ahead of our new Autumn Sale? Browse them here! jlist.com/shop/adult-t...
September 10, 2026 at 2:11 AM
jlist.com
The best tentacles are perverted tentacles. Sauce is High School DxD.

J-List has all the top ero toys in stock during our 29th Anniversary Sale. Which do you want to pick up? jlist.com/shop/adult-t...
October 5, 2025 at 2:10 AM
jlist.com
J-List has new and restocked ero products for you during our Black Day "singles" sale. Start browsing here! jlist.com/shop/adult-t...

Sauce is High School DxD.
April 9, 2026 at 2:10 AM
maryamlustberg.bsky.social
T-DXd treatment was associated with response rates in patients with advanced HER2-amplified solid tumors identified by cfDNA liquid biopsy testing.

ascopubs.org/doi/10.1200/...
Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial...
PURPOSEHERALD/EPOC1806 was conducted as a multicenter phase II trial assessing trastuzumab deruxtecan (T-DXd) therapy for patients with human epidermal growth factor receptor 2 (HER2)–amplified progre...
ascopubs.org
November 12, 2024 at 2:13 AM